Captor Therapeutics Presents Compelling In Vivo

Data confirm strong anticancer activity of two lead compounds in CT-01 programResults support advancement of CT-01 compounds towards IND expected in late...

Related Keywords

Poland ,Polish ,Jakub Radzewicz ,Bevacizumab Avastin ,Atezolizumab Tecentriq ,Guillaume Van Renterghem ,Company Optigrade ,International Investor Relations ,Linkedin ,Twitter ,Chief Executive Officer ,Investigational New Drug Application ,Captor Therapeutic ,Overall Survival ,Overall Response Rate ,Targeted Protein Degradation ,Captor Therapeutics ,Investor Relations ,Warsaw Stock Exchange Ctx ,